FTO and acute myeloid leukemia: Another report suggests that isocitrate dehydrogenase 1 or 2 (IDH1/2) mutant tumors account for ~20% of AML cases, causing aberrant metabolite D-2-hydroxyglutarate (D2HG) production [154], which acts as a competitive inhibitor of FTO through suppressing the activities of alpha-ketoglutarate-dependent enzymes.